Yes, the chapter regarding progressive cognitive symptoms management (Chapter 4.3.1) mentions the pharmacological treatments for symptomaitc relief in dementia especially for Alzheimer’s disease. They include Cholinesterase inhibitor (ChEI) (e.g., Donepezil, Rivastigmine, Galantamine) and N-methyl-D-aspartate (NMDA) receptor antagonist (e.g., Memantine) (Department of Health, 2017b, pp. 29-30). These medicines are included in the Hospital Authority Drug Formulary in Hong Kong (The Government of the Hong Kong SAR, 2015, February 25).

References:

Department of Health. (2017b). Hong Kong Reference Framework for Preventive Care for Older Adults in Primary Care Settings: Module on Cognitive Impairment. Retrieved from https://www.fhb.gov.hk/pho/rfs/english/pdf_viewer.html?file=download215&title=string258&titletext=string189&htmltext=string189&resources=07_Module_on_Cognitive_Impairment

The Government of the Hong Kong SAR. (2015, February 25). LCQ17: Dementia [Press release]. Retrieved from https://www.info.gov.hk/gia/general/201502/25/P201502250512.htm